[MP Test] 56th European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

Milan, Italy 01 October 2024 - 17 April 2025

Antibiotic Resistance Lozenge

27 Jan 2025

Flurbiprofen is a nonsteroidal, anti-inflammatory, and antipyretic drug¹ that is completely absorbed after oral administration. Several studies have shown that flurbiprofen was proven to be safe, well tolerated, and effective in relieving throat pain, swollen or inflamed throat, and difficulty in swallowing.^2–4 It is the preferred first line treatment in patients with inflamed or swollen, and painful throat. ⁴

References:
1. Gonzales-Younes I, et al. J Pharm Sci 1991;80:820–823. 2. de Looze F, et al. Eur J Gen Pract 2016;22:111–118. 3. Russo M, et al. Br J Gen Pract 2013;63:e149–55. 4. Aspley S, et al. Curr Med Res Opin 2016;32:1529–1538.

Antibiotic Resistance Lozenge

27 Jan 2025

Product Highlight - Enhertu

12 Dec 2024

Trastuzumab deruxtecan 100 mg powder for concentrate for solution for infusion

Product Highlight - Enhertu

12 Dec 2024

[PD TEST]48-week data ASSERT odevixibat’s role in ALGS

11 Oct 2024 by

Pooled analysis of the ASSERT and ASSERT-EXT studies show sustained improvements in multiple parameters with odevixibat in individuals with Alagille syndrome (ALGS), thus reinforcing its role in the treatment of this multisystem genetic disorder.

[PD TEST]48-week data ASSERT odevixibat’s role in ALGS

11 Oct 2024

Surgery a potential treatment for GERD-related heartburn

05 Aug 2024 by

Surgery may be a potential treatment for patients who have persistent heartburn due to gastroesophageal reflux disease (GERD) despite treatment with proton-pump inhibitors (PPIs), according to a recent study.

Surgery a potential treatment for GERD-related heartburn

05 Aug 2024

Tobacco smoke exposure early in life ups paediatric IBD risk

03 Jun 2024 by

A Scandinavian population-based birth cohort study reveals that children who were exposed to tobacco smoke during their early childhood have an increased risk of developing inflammatory bowel disease (IBD) later in life.

Tobacco smoke exposure early in life ups paediatric IBD risk

03 Jun 2024

Dupilumab sustains histological remission in children with EoE

29 May 2024 by

Treatment with higher-dose dupilumab results in sustained improvements in histologic and endoscopic measures of eosinophilic esophagitis (EoE) in children, regardless of prior use of swallowed topical corticosteroids (STCs), according to a subanalysis presented at ESPGHAN 2024.

Dupilumab sustains histological remission in children with EoE

29 May 2024

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024 by

Maralixibat may have a role in treating a broader profile of children with PFIC, including those who have had biliary diversion surgery and those with MDR3 deficiency, suggest subgroup analyses from the phase III MARCH/MARCH-ON trials

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024

High-resolution anorectal manometry detects HD in children ≤2 years old

28 May 2024 by

High-resolution anorectal manometry (HR‐ARM) can be a noninvasive primary screening tool for Hirschsprung’s disease (HD), particularly in children ≤2 years old, as shown in a comprehensive retrospective analysis.

High-resolution anorectal manometry detects HD in children ≤2 years old

28 May 2024

Mum’s infection during pregnancy may raise newborn’s risk of IBD

23 May 2024 by

Exposure to any infection during early pregnancy or to a gastrointestinal infection during late pregnancy contributes to the increased likelihood of inflammatory bowel disease (IBD) development, especially Crohn’s disease, in the offspring, according to a study.

Mum’s infection during pregnancy may raise newborn’s risk of IBD

23 May 2024

Children, teens with EoE respond to budesonide oral suspension

22 May 2024 by

Budesonide oral suspension is well tolerated and superior to placebo at inducing remission in paediatric patients with eosinophilic esophagitis (EoE), with the high-dose formulation offering the best results, according to the results of the phase II/III PEDEOS-1 trial.

Children, teens with EoE respond to budesonide oral suspension

22 May 2024